Investment Analysts’ Weekly Ratings Updates for Delcath Systems (DCTH)

Several brokerages have updated their recommendations and price targets on shares of Delcath Systems (NASDAQ: DCTH) in the last few weeks:

• 8/10/2026 – Delcath Systems was upgraded by Zacks Research from “hold” to “strong-buy”.
• 8/8/2026 – Delcath Systems was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/7/2026 – Delcath Systems had its “sell (d+)” rating reaffirmed by Weiss Ratings.
• 8/7/2026 – Delcath Systems had its “buy” rating reaffirmed by HC Wainwright. They now have a $32.00 price target on the stock, up from $30.00.
• 8/6/2026 – Delcath Systems had its price target raised by BTIG Research from $17.00 to $21.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Delcath Systems had its “buy” rating reaffirmed by BTIG Research. They now have a $17.00 price target on the stock.
• 7/7/2026 – Delcath Systems was upgraded by Zacks Research from “strong sell” to “hold”.

Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.